Evidence map›Paper›PMID 39287725›Full record

ArticleBulletin of experimental biology and medicine2024

Influence of Redox-Active Chitosan-Polyaminoxyl Micelles Loaded with Daunorubicin on Activity of Nrf2 Transcription Factor.

A A Balakina, V I Amozova, V D Sen'

Abstract read
PubMed Publisher
In one paragraph

Article in Bulletin of experimental biology and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

A A BalakinaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Science, Chernogolovka, Moscow Region, Russia. balakina@icp.ac.ru.
V I AmozovaFederal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Science, Chernogolovka, Moscow Region, Russia.
V D Sen'Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Science, Chernogolovka, Moscow Region, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A new system for delivery of anthracycline antibiotics based on chitosan-polyaminoxyls (CPA) was studied in a model of non-tumor (human embryonic mesenchymal stem cells) and tumor cells (human hepatocellular carcinoma) in vitro. The presence of CPA micelles considerably suppresses daunorubicin-induced ROS generation in normal cells without affecting this process in tumor cells. CPA micelles do not reduce the cytotoxic effect of daunorubicin and do not prevent its accumulation in cells. The use of CPA significantly increases accumulation of Nrf2 transcription factor in the nuclei of both normal and tumor cells in comparison with free daunorubicin. Increased nuclear translocation of Nrf2 leads to a significant increase in the expression of its target gene TXN1, but not the NQO1, GPX1, and HMOX1 genes, the increased expression of which can lead to the development of resistance to anthracycline antibiotics. Redox-active CPA micelles have great potential for the development of nanoparticles for the transport of anthracycline antibiotics in experimental tumor chemotherapy, and also as promising activators of Nrf2 transcription factor.

Indexed as

ChitosanDaunorubicinMicellesNF-E2-Related Factor 2Antibiotics, AntineoplasticCarcinoma, HepatocellularDrug CarriersHep G2 CellsHumansLiver NeoplasmsOxidation-ReductionReactive Oxygen SpeciesAntibiotics, AntineoplasticChitosanDaunorubicinDrug CarriersMicellesNFE2L2 protein, humanNF-E2-Related Factor 2Reactive Oxygen Speciesaminoxylschitosandaunorubicintranscription factor Nrf2

Identifiers

PMID39287725

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.